Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
Conditions
Anatomic Stage III Breast Cancer AJCC v8 · Anatomic Stage IV Breast Cancer AJCC v8 · Invasive Breast Carcinoma · Locally Advanced Breast Carcinoma · Metastatic Breast Carcinoma · Metastatic HER2-Low Breast Carcinoma · Metastatic HER2-Positive Breast Carcinoma · Metastatic Hormone Receptor-Positive Breast Carcinoma · Metastatic Malignant Solid Neoplasm · Metastatic Triple-Negative Breast Carcinoma · Unresectable Breast Carcinoma · Unresectable HER2-Low Breast Carcinoma · Unresectable HER2-Positive Breast Carcinoma · Unresectable Hormone Receptor-Positive Breast Carcinoma · Unresectable Malignant Solid Neoplasm · Unresectable Triple-Negative Breast Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Principal Investigator (Filipa Lynce)Washington University School of Medicine, St Louis, Missouri, United States
Contact: Principal Investigator (Andrew Davis)
Study leads
Filipa Lynce
Principal Investigator
Dana-Farber - Harvard Cancer Center LAO